ZA201203325B - Methods and compositions for treating solid tumors and other malignancies - Google Patents
Methods and compositions for treating solid tumors and other malignanciesInfo
- Publication number
- ZA201203325B ZA201203325B ZA2012/03325A ZA201203325A ZA201203325B ZA 201203325 B ZA201203325 B ZA 201203325B ZA 2012/03325 A ZA2012/03325 A ZA 2012/03325A ZA 201203325 A ZA201203325 A ZA 201203325A ZA 201203325 B ZA201203325 B ZA 201203325B
- Authority
- ZA
- South Africa
- Prior art keywords
- malignancies
- compositions
- methods
- solid tumors
- treating solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26234209P | 2009-11-18 | 2009-11-18 | |
| US29203210P | 2010-01-04 | 2010-01-04 | |
| PCT/US2010/056942 WO2011062939A1 (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201203325B true ZA201203325B (en) | 2013-01-30 |
Family
ID=43384585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/03325A ZA201203325B (en) | 2009-11-18 | 2012-05-07 | Methods and compositions for treating solid tumors and other malignancies |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20120232087A1 (enExample) |
| EP (1) | EP2501370A1 (enExample) |
| JP (1) | JP2013511526A (enExample) |
| KR (1) | KR20120107962A (enExample) |
| CN (2) | CN102665700A (enExample) |
| AU (1) | AU2010322114B2 (enExample) |
| BR (1) | BR112012011823A2 (enExample) |
| CA (1) | CA2781210A1 (enExample) |
| CL (1) | CL2012001271A1 (enExample) |
| IL (1) | IL219636A0 (enExample) |
| MA (1) | MA33739B1 (enExample) |
| MX (1) | MX2012005695A (enExample) |
| NZ (1) | NZ599964A (enExample) |
| PH (1) | PH12012500911A1 (enExample) |
| RU (1) | RU2012125152A (enExample) |
| TN (1) | TN2012000205A1 (enExample) |
| WO (1) | WO2011062939A1 (enExample) |
| ZA (1) | ZA201203325B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2501236B1 (en) | 2009-11-18 | 2017-03-29 | Plexxikon Inc. | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
| EP2715366B1 (en) * | 2011-06-02 | 2017-07-19 | Novartis AG | Biomarkers for hedgehog inhibitor therapy |
| WO2013106812A1 (en) * | 2012-01-12 | 2013-07-18 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| JP6293770B2 (ja) * | 2012-11-05 | 2018-03-14 | ナント ホールディングス アイピー，エルエルシー | ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体 |
| CN103524535B (zh) * | 2013-10-16 | 2016-07-13 | 苏州云轩医药科技有限公司 | 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物 |
| WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| KR20200125758A (ko) | 2017-10-27 | 2020-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리딘 카보닐 유도체 및 trpc6 억제제로서 이의 치료학적 용도 |
| EP3817743A4 (en) * | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| US20210346385A1 (en) * | 2018-09-21 | 2021-11-11 | MSB Holdings, Inc | Taste-masked dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| KR101464384B1 (ko) | 2005-11-22 | 2014-11-21 | 쿠도스 파마슈티칼스 리미티드 | ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체 |
| UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| JP5227321B2 (ja) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
| US8536168B2 (en) * | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
| ES2569941T3 (es) * | 2007-06-07 | 2016-05-13 | Novartis Ag | Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog |
| US8153633B2 (en) * | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009112266A1 (en) * | 2008-03-12 | 2009-09-17 | Ludwig-Maximilians-Universität | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| CN102066353B (zh) * | 2008-04-29 | 2013-12-11 | 伊莱利利公司 | 二取代的酞嗪Hedgehog通路拮抗剂 |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
-
2010
- 2010-11-17 JP JP2012539987A patent/JP2013511526A/ja not_active Ceased
- 2010-11-17 CN CN2010800517592A patent/CN102665700A/zh active Pending
- 2010-11-17 PH PH1/2012/500911A patent/PH12012500911A1/en unknown
- 2010-11-17 CA CA2781210A patent/CA2781210A1/en not_active Abandoned
- 2010-11-17 CN CN201410410334.6A patent/CN104224791A/zh active Pending
- 2010-11-17 RU RU2012125152/15A patent/RU2012125152A/ru unknown
- 2010-11-17 AU AU2010322114A patent/AU2010322114B2/en not_active Ceased
- 2010-11-17 MX MX2012005695A patent/MX2012005695A/es not_active Application Discontinuation
- 2010-11-17 KR KR1020127015545A patent/KR20120107962A/ko not_active Withdrawn
- 2010-11-17 BR BR112012011823A patent/BR112012011823A2/pt not_active IP Right Cessation
- 2010-11-17 WO PCT/US2010/056942 patent/WO2011062939A1/en not_active Ceased
- 2010-11-17 NZ NZ599964A patent/NZ599964A/en not_active IP Right Cessation
- 2010-11-17 EP EP10782767A patent/EP2501370A1/en not_active Withdrawn
- 2010-11-17 US US13/509,857 patent/US20120232087A1/en not_active Abandoned
-
2012
- 2012-05-07 ZA ZA2012/03325A patent/ZA201203325B/en unknown
- 2012-05-07 IL IL219636A patent/IL219636A0/en unknown
- 2012-05-07 TN TNP2012000205A patent/TN2012000205A1/en unknown
- 2012-05-11 MA MA34856A patent/MA33739B1/fr unknown
- 2012-05-16 CL CL2012001271A patent/CL2012001271A1/es unknown
-
2014
- 2014-10-09 US US14/510,713 patent/US20150025074A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2501370A1 (en) | 2012-09-26 |
| KR20120107962A (ko) | 2012-10-04 |
| JP2013511526A (ja) | 2013-04-04 |
| RU2012125152A (ru) | 2013-12-27 |
| WO2011062939A1 (en) | 2011-05-26 |
| PH12012500911A1 (en) | 2012-11-26 |
| MX2012005695A (es) | 2012-06-13 |
| AU2010322114A1 (en) | 2012-05-31 |
| MA33739B1 (fr) | 2012-11-01 |
| CA2781210A1 (en) | 2011-05-26 |
| NZ599964A (en) | 2014-08-29 |
| CN102665700A (zh) | 2012-09-12 |
| AU2010322114B2 (en) | 2014-07-31 |
| CN104224791A (zh) | 2014-12-24 |
| US20120232087A1 (en) | 2012-09-13 |
| CL2012001271A1 (es) | 2012-10-12 |
| IL219636A0 (en) | 2012-07-31 |
| BR112012011823A2 (pt) | 2019-09-24 |
| US20150025074A1 (en) | 2015-01-22 |
| TN2012000205A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| HRP20190214T1 (hr) | Pripravci i metode za liječenje purpure | |
| SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
| PL2434891T3 (pl) | Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych | |
| PT2200431T (pt) | Novos métodos e composições para o tratamento do cancro | |
| PL2173379T3 (pl) | Kompozycje oraz sposoby leczenia i diagnozowania nowotworu | |
| PL2340042T3 (pl) | Sposoby i kompozycje do leczenia raka | |
| EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
| IL215932A0 (en) | Compositions and methods for treating burns | |
| IL219636A0 (en) | Methods and compositions for treating solid tumors and other malignancies | |
| PL2512502T3 (pl) | Sposoby i kompozycje do likwidacji guzów | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| IL215772A0 (en) | Composition for the treatment of prostate cancer | |
| EP2231185A4 (en) | METHOD AND COMPOSITIONS FOR TREATING LIQUID TUMORS | |
| SI2235002T1 (sl) | Spojine 4-piridinona in njihova uporaba za zdravljenje raka | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| EP2300608A4 (en) | METHODS OF TREATING SOLID TUMORS | |
| PL2187967T3 (pl) | Sposoby i kompozycje do leczenia raka | |
| IL199881A0 (en) | Compositions and methods for treating hematopietic malignancies | |
| EP2391211A4 (en) | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | |
| EP2384115A4 (en) | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANT TUMORS | |
| IL204945A0 (en) | Compositions and methods for inhibiting tumor progression | |
| EP2137213A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER | |
| IL217764A0 (en) | Methods and compositions for treating leukemia | |
| GB0822345D0 (en) | Methods and compositions for cancer prognosis |